company background image
APLT

Applied Therapeutics NasdaqGM:APLT Stock Report

Last Price

US$1.35

Market Cap

US$78.1m

7D

3.8%

1Y

9.8%

Updated

02 Jun, 2023

Data

Company Financials +

Applied Therapeutics, Inc.

NasdaqGM:APLT Stock Report

Mkt Cap: US$78.1m

APLT Stock Overview

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States.

APLT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Applied Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Applied Therapeutics
Historical stock prices
Current Share PriceUS$1.35
52 Week HighUS$2.18
52 Week LowUS$0.50
Beta1.89
1 Month Change-19.16%
3 Month Change39.18%
1 Year Change9.76%
3 Year Change-96.76%
5 Year Changen/a
Change since IPO-85.64%

Recent News & Updates

Recent updates

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11
Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26
Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Feb 18
How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics to resume galactosemia study for AT-007

Feb 02

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Nov 24
Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Applied Therapeutics EPS misses by $0.21

Nov 12

Shareholder Returns

APLTUS BiotechsUS Market
7D3.8%1.3%2.1%
1Y9.8%12.2%2.4%

Return vs Industry: APLT underperformed the US Biotechs industry which returned 11% over the past year.

Return vs Market: APLT exceeded the US Market which returned -1% over the past year.

Price Volatility

Is APLT's price volatile compared to industry and market?
APLT volatility
APLT Average Weekly Movement12.8%
Biotechs Industry Average Movement11.1%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: APLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: APLT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201626Shoshana Shendelmanhttps://www.appliedtherapeutics.com

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.

Applied Therapeutics, Inc. Fundamentals Summary

How do Applied Therapeutics's earnings and revenue compare to its market cap?
APLT fundamental statistics
Market CapUS$78.10m
Earnings (TTM)-US$69.52m
Revenue (TTM)US$10.66m

7.3x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
APLT income statement (TTM)
RevenueUS$10.66m
Cost of RevenueUS$0
Gross ProfitUS$10.66m
Other ExpensesUS$80.18m
Earnings-US$69.52m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.20
Gross Margin100.00%
Net Profit Margin-652.20%
Debt/Equity Ratio0%

How did APLT perform over the long term?

See historical performance and comparison